Agena Announces MassARRAY® Technology Selected for Participation in CANCER-ID Consortium
San Diego, CA, July 24, 2018 – Agena Bioscience, a global provider of molecular testing solutions, announced today that it has been selected for participation in the CANCER-ID Consortium. Agena’s MassARRAY® System will support mutation detection from liquid biopsy samples as part of the consortium’s key work packages in lung cancer and breast cancer. “We are... Read more